Your browser is no longer supported. Please, upgrade your browser.
Settings
IDRA Idera Pharmaceuticals, Inc. daily Stock Chart
IDRA [NASD]
Idera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own0.30% Shs Outstand203.21M Perf Week-2.60%
Market Cap380.00M Forward P/E- EPS next Y-0.40 Insider Trans- Shs Float165.74M Perf Month-5.56%
Income-50.20M PEG- EPS next Q-0.09 Inst Own24.60% Short Float2.92% Perf Quarter-16.14%
Sales16.00M P/S23.75 EPS this Y28.70% Inst Trans1.54% Short Ratio1.94 Perf Half Y12.65%
Book/sh0.41 P/B4.56 EPS next Y4.80% ROA-55.10% Target Price5.17 Perf Year17.61%
Cash/sh0.32 P/C5.82 EPS next 5Y- ROE-60.80% 52W Range1.30 - 2.87 Perf YTD24.67%
Dividend- P/FCF- EPS past 5Y21.70% ROI-37.30% 52W High-34.84% Beta2.18
Dividend %- Quick Ratio8.80 Sales past 5Y214.10% Gross Margin- 52W Low43.85% ATR0.14
Employees62 Current Ratio8.80 Sales Q/Q-33.30% Oper. Margin- RSI (14)37.24 Volatility6.57% 6.44%
OptionableYes Debt/Eq0.00 EPS Q/Q8.60% Profit Margin- Rel Volume2.34 Prev Close1.95
ShortableYes LT Debt/Eq0.00 EarningsNov 06 Payout- Avg Volume2.50M Price1.87
Recom1.70 SMA20-10.53% SMA50-11.21% SMA200-6.49% Volume5,700,858 Change-4.10%
Nov-09-17Initiated H.C. Wainwright Buy $4
Apr-25-17Initiated Robert W. Baird Outperform $5
Mar-22-17Initiated JMP Securities Mkt Outperform
Feb-01-17Reiterated Wedbush Outperform $6
Jan-06-16Initiated Wedbush Outperform $6
Jun-15-15Initiated JP Morgan Overweight
Mar-03-14Initiated Cowen Outperform
Mar-24-10Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $10
Nov-21-08Initiated Noble Financial Buy
Oct-27-08Upgrade Susquehanna Financial Negative → Neutral
Aug-06-08Downgrade Canaccord Adams Buy → Hold
May-07-08Downgrade Janney Mntgmy Scott Buy → Neutral
May-02-08Downgrade Susquehanna Financial Neutral → Negative $11
Dec-08-17 01:03PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : December 8, 2017 Capital Cube
Dec-04-17 07:04AM  3 Top Stocks Under $5 Motley Fool
Dec-01-17 07:20AM  Wired News Idera Pharma Gets Fast Track Designation for IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma ACCESSWIRE
Nov-29-17 07:30AM  U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma GlobeNewswire
Nov-28-17 08:00AM  Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-27-17 04:01PM  Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
02:13PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
Nov-21-17 07:33AM  Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : November 21, 2017 Capital Cube
Nov-17-17 12:07PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : November 17, 2017 Capital Cube
Nov-10-17 08:37AM  Is the Options Market Predicting a Spike in Idera (IDRA) Stock? Zacks
Nov-09-17 01:12PM  Why Idera Pharmaceuticals Inc. Jumped Higher Today Motley Fool +14.12%
09:20AM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
07:30AM  Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC) GlobeNewswire
Nov-08-17 08:00AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Idera Pharmaceuticals ACCESSWIRE -5.35%
Nov-07-17 10:22AM  ETFs with exposure to Idera Pharmaceuticals, Inc. : November 7, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE
Nov-06-17 04:39PM  Idera reports 3Q loss Associated Press
04:02PM  Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-17 05:26PM  Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today Motley Fool +7.01%
Oct-26-17 12:18PM  Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today Motley Fool -27.41%
07:00AM  Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Oct-24-17 04:01PM  Idera Pharmaceuticals Provides Corporate Governance Update GlobeNewswire
04:01PM  Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-13-17 10:56AM  ETFs with exposure to Idera Pharmaceuticals, Inc. : October 13, 2017 Capital Cube
Oct-02-17 10:54AM  ETFs with exposure to Idera Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-21-17 07:47AM  3 Small-Cap Biotech Stocks to Buy This Fall Motley Fool
Sep-20-17 06:57PM  Is It Time To Buy Idera Pharmaceuticals Inc (IDRA)? Simply Wall St.
Sep-19-17 05:46PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : September 19, 2017 Capital Cube
Sep-18-17 12:56PM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube +5.69%
Sep-12-17 08:47AM  Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4% Zacks -7.85%
08:10AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Idera Pharmaceuticals ACCESSWIRE
Sep-11-17 12:16PM  Here's Why Idera Pharmaceuticals, Inc. Is Surging Today Motley Fool +14.36%
09:46AM  Achillion Shares Are Plunging on Termination of Hepatitis C Pact TheStreet.com
09:03AM  US STOCKS-Wall St set for relief rally as Irma, N.Korea fears ease Reuters
Sep-10-17 07:15AM  Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy PR Newswire
Sep-08-17 07:30AM  Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory GlobeNewswire
Sep-06-17 01:00PM  Idera to Host Investor Conference Call on Monday, September 11, 2017 at 9:00 A.M. E.T. GlobeNewswire
Aug-11-17 11:00AM  Idera to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-17 07:49PM  Idera reports 2Q loss Associated Press
05:00PM  Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Jul-11-17 02:40PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : July 11, 2017 Capital Cube +5.65%
Jun-24-17 11:42AM  3 Stocks That Could Double Your Money Motley Fool
Jun-23-17 08:03AM  3 Stocks to Watch on Friday: Bed Bath & Beyond Inc. (BBBY), Sonic Corporation (SONC) and Idera Pharmaceuticals Inc (IDRA) InvestorPlace +11.56%
Jun-22-17 04:30PM  Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma GlobeNewswire
Jun-05-17 11:00AM  Idera to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
Jun-01-17 01:52PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : June 1, 2017 Capital Cube
May-22-17 01:46PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : May 22, 2017 Capital Cube
May-11-17 04:53PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 11:33AM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-05-17 05:06PM  Idera Pharmaceuticals, Inc. Value Analysis (NASDAQ:IDRA) : May 5, 2017 Capital Cube -11.96%
04:34PM  Here's Why Idera Pharmaceuticals, Inc. Is Sinking Today Motley Fool
May-04-17 06:45PM  Idera reports 1Q loss Associated Press
04:01PM  Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
08:49AM  Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IDRA-US : May 4, 2017 Capital Cube
Apr-21-17 09:26AM  The Market In 5 Minutes Benzinga
07:30AM  Today's Research Reports on Biotech Stocks to Watch: Idera Pharmaceuticals and ZIOPHARM Oncology Accesswire
Apr-18-17 04:01PM  Idera Pharmaceuticals Announces Organizational Update GlobeNewswire
Apr-11-17 07:00AM  Idera Pharmaceuticals Advances Investigational Treatment Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma GlobeNewswire
Apr-05-17 07:00AM  Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting GlobeNewswire -10.53%
07:00AM  Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting
Apr-03-17 08:21AM  3 Stocks the Smartest Investors are Buying Right Now Motley Fool
08:21AM  3 Stocks the Smartest Investors are Buying Right Now at Motley Fool
Mar-27-17 03:59PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
03:59PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : March 27, 2017
Mar-25-17 12:03PM  3 Stocks That Could Double Your Money Motley Fool
12:03PM  3 Stocks That Could Double Your Money at Motley Fool
10:10AM  Analyst Calls for Exponential Upside for Idera Pharmaceuticals 24/7 Wall St.
10:10AM  Analyst Calls for Exponential Upside for Idera Pharmaceuticals
Mar-23-17 09:30AM  Idera Pharmaceuticals and XOMA Find Paths to Financial Growth Accesswire
Mar-22-17 09:08AM  Idera Pharma Shares Could Be A Four-Bagger, JMP Says Benzinga +19.14%
09:08AM  Idera Pharma Shares Could Be A Four-Bagger, JMP Says
06:55AM  Coverage initiated on Idera Pharma by JMP Securities
Mar-21-17 01:04PM  IDERA PHARMACEUTICALS, INC. Financials -6.28%
Mar-17-17 11:38AM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
11:38AM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
09:57AM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017
Mar-15-17 07:25PM  Idera posts 4Q profit Associated Press
07:25PM  Idera posts 4Q profit
05:05PM  IDERA PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
04:30PM  Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update GlobeNewswire
Mar-13-17 05:00PM  IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pr
Mar-02-17 07:30AM  Idera to Present at the 37th Annual Cowen and Company Health Care Conference GlobeNewswire +9.09%
Mar-01-17 08:30AM  Idera Pharmaceuticals (IDRA) Looks Good: Stock Up 13.3%
Feb-27-17 12:45PM  Idera Drug Combo Study Posts Positive Results at Investopedia
Feb-24-17 11:30AM  Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinic GlobeNewswire
Feb-22-17 03:53PM  3 Biotech Stocks You May Be Overlooking at Motley Fool
Feb-06-17 08:00AM  Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development GlobeNewswire
Jan-09-17 08:01AM  IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-17 04:03PM  IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-04-17 12:00PM  Idera to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.00%
11:07AM  ETFs with exposure to Idera Pharmaceuticals, Inc. : January 4, 2017
Dec-21-16 12:27PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : December 21, 2016
Dec-15-16 10:18AM  Is the Options Market Predicting a Spike in Idera Pharmaceuticals (IDRA) Stock?
Dec-13-16 11:44AM  Why You Shouldn't Bet Against Idera (IDRA) Stock
Dec-12-16 11:54PM  How RAIT Financial Trust (RAS) Stacks Up Against Its Peers at Insider Monkey -5.33%
05:41PM  Is Idera Pharmaceuticals Inc (IDRA) a Good Stock to Buy? at Insider Monkey
Dec-09-16 12:20PM  ETFs with exposure to Idera Pharmaceuticals, Inc. : December 9, 2016
Dec-08-16 08:15AM  Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016
Dec-02-16 11:03AM  Why Idera Pharmaceuticals (IDRA) Could Be Positioned for a Surge
Nov-29-16 09:36AM  Idera Gets $15 Million for Shelved GI Drug (IDRA) at Investopedia
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pillar Invest Corp10% OwnerDec 15Sale1.9133,83064,5270Dec 15 05:50 PM
Pillar Invest Corp10% OwnerDec 14Sale2.001,166,1702,332,6010Dec 15 05:50 PM
Pillar Invest Corp10% OwnerDec 13Sale1.931,100,0002,118,1700Dec 15 05:50 PM
BAKER BROS. ADVISORS LPDirectorOct 26Buy1.508,000,00012,000,00016,557,473Oct 30 05:12 PM
Pillar Invest CorpDirectorMay 01Sale2.26450,8151,018,4360May 03 07:38 PM
Pillar Invest CorpDirectorApr 25Sale2.29890,5932,037,9440Apr 26 05:59 PM
Pillar Invest CorpDirectorApr 24Sale2.29437,8291,002,0590Apr 26 05:59 PM